Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development

Pharmacological Reports

Volumn 58, Issue 4, 2006, Pages 453-472

  Baranczewski, Paweł ^a,c   Stańczak, Andrzej ^b   Sundberg, Kathrin ^a   Svensson, Richard ^a   Wallin, Åsa ^a   Jansson, Jenny ^a   Garberg, Per ^a   Postlind, Hans ^a  

^a BIOVITRUM AB   (Sweden)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Cytochrome P450; Drug interactions; Drug metabolism; High throughput screens; Metabolic stability

Indexed keywords

BETA NAPHTHOFLAVONE; BUFURALOL; CHLORZOXAZONE; CLOMETHIAZOLE; COUMARIN; CYTOCHROME P450; DEXAMETHASONE; DEXTROMETHORPHAN; DICLOFENAC; DIMETHYLANILINE MONOOXYGENASE; DRUG METABOLIZING ENZYME; ETHOXYRESORUFIN; FURAFYLLINE; GLITAZONE DERIVATIVE; GLUCURONOSYLTRANSFERASE; IMIPRAMINE; MEPHENYTOIN; METHOXSALEN; MIDAZOLAM; NEW DRUG; OMEPRAZOLE; PACLITAXEL; PHENACETIN; QUINIDINE; RIFAMPICIN; SULFAPHENAZOLE; TESTOSTERONE; TRANYLCYPROMINE; UNINDEXED DRUG; WARFARIN;

AUTOMATION; CALCULATION; COMPETITIVE INHIBITION; COMPUTER MODEL; CRYOPRESERVATION; DATA ANALYSIS SOFTWARE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STABILITY; DRUG TRANSFORMATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SPECIFICITY; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PREDICTION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; TISSUE SLICE;

EID: 33748636018     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Alvan G, Bechtel P, Iselius L, Gundert-Remy U: Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol, 1999, 39, 533-537.
2. Andersson TB, Bredberg E, Ericsson H, Sjoberg H: An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab Dispos, 2004, 32, 715-721.
3. Andersson TB, Bredberg E, Ericsson H, Sjoberg H: Response: predicting the clearance of CYP2C9 substrates. Drug Metab Dispos, 2004, 32, 1523.
4. Andersson TB, Sjoberg H, Hoffmann KJ, Boobis AR, Watts P, Edwards RJ, Lake BG et al.: An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab Dispos, 2001, 29, 712-720.
5. Asseffa A, Smith SJ, Nagata K, Gillette J, Gelboin HV, Gonzalez FJ: Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus. Arch Biochem Biophys, 1989, 274, 481-490.
6. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ: The influence of non-specific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos, 2002, 30, 1497-1503.
7. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ: Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol, 1994, 37, 221-225.
8. Baranczewski P, Kallin A, Andersson A, Hagigi S, Åberg M, Postlind H, Mankowitz L: Development of an assay using 4-trifluoromethylumbelliferyl as a marker substrate for assessment of drug-drug interactions to multiple isoforms of UDP-glucuronosyltranferses. Assay Drug Develop Tech, 2004, 2, 345-352.
9. Bergstrom RF, Peyton AL, Lemberger L: Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol. Ther, 1992, 51, 239-248.
10. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R et al.: Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA, 1998, 95, 12208-12213.
11. Bertilsson L: Geographical/Interracial differences in polymorphic drug oxidation. Clin Pharmacokin Con, 1995, 29, 192-209.
12. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J et al.: The conduct of in vitro and in vivo drug-drug-interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos, 2003, 31, 815-832.
13. Bleicher KH, Böhm H-J, Muller K, Alanine AI: Hit and lead generation: beyond high-throughput screening. Nat Rev: Drug Discov, 2003, 2, 369-378.
14. Clarke SE, Jones BC: Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In: Drug-Drug Interactions. Ed. Rodriques AD, Marcel Dekker Inc., New York, USA, 2002, 55-88.
15. Crespi CL: Expression of cytochrome P450 cDNAs in human B lymphoblastoid cells: applications to toxicology and metabolite analysis. Methods Enzymol, 1991, 206, 123-129.
16. Crespi CL: Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res, 1995, 26, 179-235.
17. Ekins S, de Groot MJ, Jones JP: Pharmacophore and three-dimensional quantitative structure-activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos, 2001, 29, 936-944.
18. Ekins S, Erickson JA: A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos, 2002, 30, 96-99.
19. Ethell BT, Beaumont K, Rance DJ, Burchell B: Use of cloned and expressed human UDP-glucuronosyltransferases for the assessment of human drug conjugation and identification of potential drug interactions. Drug Metab Dispos, 2001, 29, 623-646.
20. Evans WE, McLeod HL: Pharmacogenetics - drug disposition, drug targets, and side effects. N Eng J Med, 2003, 348, 538-548.
21. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999, 286, 487-491.
22. Ghanbari F, Rowland Yeo K, Lennard MS, Tucker GT, Rostami-Hodjegan A: A critical evaluation of experimental designs used in reports of mechanism based enzyme inhibition (MBI) studies and the assessment of their implications for in vitro-in vivo extrapolation. Drug Metab Rev, 2005, 37, 69.
23. Greenblat DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI: Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol, 1999, 19, 293-296.
24. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359L mutant forms. Arch Biochem Biophys, 1996, 333, 447-458.
25. Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK et al.: Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol, 1999, 39, 1189-1194.
26. Hasler JA, Estabrook R, Murray M, Pikuleva I, Waterman M, Capdevila J, Holla V et al.: Human cytochrome P450. Mol Aspects Med, 1999, 20, 1-137.
27. Heinemann A, Wischhusen F, Puschel K, Rogiers X: Standard liver volume in the Caucasian population. Liver Transpl Surg, 1999, 5, 366-368.
28. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther, 1992, 52, 231-238.
29. Houston JB: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol, 1994, 47, 1469-1479.
30. Houston JB, Carlile DJ: Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev, 1997, 29, 891-922.
31. Houston JB, Kenworthy KE, Galetin A: Typical and atypical enzyme kinetics. In: Drug Metabolising Enzymes. Cytochrome P450 and Other Enzymes in Drug Discovery and Development. Ed. Lee JS, Obach RS, Fisher M B, Marcel Dekker Inc., New York, USA and FontisMedia S.A., Lausanne, Switzerland, 2003, 211-254.
32. Hutzler JM, Messing DM, Wienkers LC: Predicting drug-drug interactions in drug discovery: where are we now and where are we going? Curr Opin Drug Disc Develop, 2005, 8, 51-58.
33. Ingelman-Sundberg M, Oscarson M, McLellan RA: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci, 1999, 20, 342-349.
34. Ingelman-Sundberg M: Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology, 2002, 181-182, 447-452.
35. Jenkins KM, Angeles R, Quintos MT, Xu R, Kassel DB, Rourick RA: Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. J Pharm Biomed Anal, 2004, 34, 989-1004.
36. Kalvass JC, Tess DA, Giragossian C, Linhares MC, Maurer TS: Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab Dispos, 2001, 29, 1332-1336.
37. Kanamitsu SI, Ito K, Sugiyama Y: Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmakinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharmacol Res, 2000, 17, 336-343.
38. Kantola T, Kivisto KT, Neuvonen PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther, 1998, 64, 177-182.
39. Kariv I, Fereshteh MP, Oldenburg KR: Development of miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. J Biomol Screen, 2001, 6, 91-99.
40. Kassel DB: Applications of high throughput ADME in drug discovery. Curr Opin Chem Biol, 2004, 8, 339-345.
41. King CD, Rios GR, Green MD, Tephly TR: UDP-glucuronosyl- transferases. Curr Drug Metab, 2001, 1, 143-161.
42. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev: Drug Discov, 2004, 3, 711-715.
43. Korfmacher WA: Using mass spectrometry for drug metabolism studies. CRC Press, Boca Raton, FL, USA, 2005.
44. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ et al.: Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 1998, 37, 4137-4147.
45. Lamberg TS, Kivisto KT, Neuvonen PJ: Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther, 1998, 63, 640-645.
46. Lee BL, Tauber MG, Sadler B, Goldstein D, Chambers HF: Atovaquone inhibits the glucuronidation and increases the plasma concentration of zidovudine. Clin Pharmacol Ther, 1996, 169, 1103-1107.
47. Lin JH: Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab, 2000, 5, 147-156.
48. Loi C-M, Young M, Randinitis E, Vassos A, Koup JR: Clinical pharmacokinetic s of troglitazone. Clin Pharmacokinet, 1999, 37, 91-104.
49. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G et al.: CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos, 2002, 30, 795-804.
50. Lusska A, Wu L, Whitlock JP Jr: Superinduction of CYP1A1 transcription by cycloheximide. Role of the DNA binding site for the liganded Ab receptor. J Biol Chem, 1992, 267, 15146-15151.
51. Ma B, Prueksaritanont T, Lin JH: Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos, 2000, 28, 125-130.
52. Mankowski DC, Ekins S: Prediction of human drug metabolizing enzyme induction. Curr Drug Metab, 2003, 4, 381-391.
53. McTavish D, Sorkin EM: Verapamil. An updated review of its pharmacodynamic and pharmacokinetics properties and therapeutic use in hypertensions. Drugs, 1989, 38, 481-503.
54. Nichols JS, Parks DJC, Thomas G, Blanchard SG: Development of a scintillation proximity assay for peroxisome proliferators-activated receptor, γ ligand binding domain. Anal Biochem, 1998, 257, 112-119.
55. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ et al.: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther, 1997, 283, 46-58.
56. Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos, 2002, 30, 831-837.
57. Pang KS, Rowland M: Hepatic clearance of drugs I: theoretical considerations of a "well-stirred" and "parallel-tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm, 1977, 5, 625-653.
58. Parkinson A: Biotransformation of xenobiotics. In: Casarett and Doull's Toxicology. The Basic Science of Poisons. Ed. Klaassen CD, McGraw-Hill Medical Publishing Division, New York, USA, 2001, 133-224.
59. Plant N: Strategies for using in vitro screens in drug metabolism. Drug Discov Today, 2004, 9, 328-336.
60. Plant N: In vitro assays: crystal balls or random guesses? Drug Discov Today, 2005, 10, 462-464.
61. Polasek TM, Elliot DJ, Lewis BC, Miners JO: Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther, 2004, 311, 996-1007.
62. Proctor NJ, Tucker GT, Rostami-Hodjegan A: Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica, 2004, 34, 151-178.
63. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev, 2002, 34, 83-448.
64. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev, 1997, 29, 413-580.
65. Riley RJ, Grime K: Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. Drug Discov Today: Technol, 2004, 1, 365-372.
66. Roberts MS, Rowland M: Hepatic elimination dispersion model. J Pharm Sci, 1985, 74, 585-587.
67. Roberts MS, Rowland M: A dispersion model of hepatic elimination. J Pharmacokinet Biopharm, 1986, 14, 227-308.
68. Rodrigues AD: Integrated P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol, 1999, 57, 465-480.
69. Rostami-Hodjegan A, Tucker GT: "In silico" simulations to assess the "in vivo" consequences of "in vitro" metabolic drug-drug interactions. Drug Discov Today: Technol, 2004, 1, 441-448.
70. Rowland M, Benet LZ, Graham GG: Clearance concept in pharmacokinetics. J Pharmacokinet Biopharm, 1973, 1, 123-136.
71. Rowland Yeo Y, Howgate EM, Tucker GT, Rostami-Hodjegan A: Predicting the clearance of CYP2C9 substrates. Drug Metab Dispos, 2004, 32, 1522.
72. Rowland Yeo K, Yeo WW: Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol, 2001, 51, 461-470.
73. Roymans D, Van Looveren C, Leone A, Parker JB, McMillian M, Johnson MD, Koganti A et al.: Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochem Pharmacol, 2004, 67, 427-437.
74. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D et al.: Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos, 2003, 31, 439-446.
75. Saraswat LD, Caserta KA, Laws K, Wei D, Jones SS, Adedoyin A: A high-throughput method for enzyme kinetic studies. J Biomol Screen, 2003, 8, 544-554.
76. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF: Structure of human microsomal cytochrome P450 2C8. J Biol Chem, 2004, 279, 9497-9503.
77. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR: Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 1994, 33, 6450-6455.
78. Shou M: Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr Opin Drug Discov Devel, 2005, 8, 66-77.
79. Silverman RB: Mechanism-based enzyme inactivators: Enzyme kinetics and mechanism. Methods Enzymol, 1995, 249, 240-283.
80. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T: Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol, 1991, 32, 504-507.
81. Smith DA: Induction and drug development. Eur J Pharm Sci, 2000, 11, 185-199.
82. Thummel KE, Wilkinson G: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol, 1998, 38, 370-381.
83. Tucker G., Houston JB, Huang S-M: Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol, 2001, 52, 107-117.
84. Tukey RH, Strassburg CP: Human glucuronosyltransferses: metabolism, expression and disease. Annu Rev Pharmacol Toxicol, 2000, 40, 581-616.
85. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO: Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos, 2004, 32, 413-423.
86. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ: Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab, 2003, 4, 423-459.
87. Wang YH, Jones DR, Hall SD: Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos, 2004, 32, 259-266.
88. White RE: High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol, 2000, 40, 133-157,
89. Wilkinson GR, Shand DG: A physiological approach to hepatic clearance. Clin Pharmacol Ther, 1975, 18, 377-390.
90. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H: Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424, 464-468.
91. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C et al.: Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science, 2004, 305, 683-686.
92. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT: Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol, 2003, 56, 433-440.
93. Wright JD, Boudinot FD, Ujhelyi MR: Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet, 1996, 30, 445-462.
94. Yamamoto T, Suzuki A, Kohno Y: High-throughput screening for the assessment of time-dependent inhibition of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica, 2004, 34, 87-101.
95. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA et al.: Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol, 1998, 56, 243-251.
96. Yeo C, Levy RH: Inhibition-based metabolic drug-drug interactions: prediction from in vitro data. J Pharm Sci, 2002, 91, 1923-1935.